Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review

Abstract

Purpose of Review To quantify the prevalence of asymptomatic pre-heart failure (pre-HF), progression to more severe stages, and associated mortality. Recent Findings A systematic review was conducted between 01 January 2010 and 12 March 2020 (PROSPERO: CRD42020176141). Data of interest included prevalence, disease progression, and mortality rates. In total, 1030 sources were identified, of which, 12 reported on pre-HF (using the ACC/AHA definition for stage B HF) and were eligible. Prevalence estimates of pre-HF ranged from 11 to 42.7% (10 sources) with higher estimates found in the elderly, in patients with hypertension, and in men. Three studies reported on disease progression with follow-up ranging from 13 months to 7 years. The incidence of symptomatic HF (HF/advanced HF) ranged from 0.63 to 9.8%, and all-cause mortality from 1.6 to 5.4%. Summary Further research is required to investigate whether early detection and intervention can slow or stop the progression from asymptomatic to symptomatic HF.

Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits

“…FL and KO mice were injected with tamoxifen to induce cardiac-specific Serca2 gene excision, and hearts were removed for ex vivo functional analysis by Langendorff methodology. Per the hypothesis guiding these studies, focus was on myocardial diastolic performance using LVEDP as a clinically meaningful parameter in relaxation function and the emergence of congestive heart failure ( 2 , 4 , 26 ). Time to 50% relaxation was also assessed as another valid parameter of heart diastolic function.…”

Guía mexicana de práctica clínica para el diagnóstico y el tratamiento de la insuficiencia cardiaca

“…Una revisión sistemática (RS) de la literatura publicada por Bergamasco et al 21 en 2022 tuvo como objetivo determinar la prevalencia de las distintos estadios de la insuficiencia cardiaca, porpuestos por AHA/ACC, progresión de la enfermedad y tasas de mortalidad 21 . Los autores incluyeron 12 estudios, de los cuales 10 reportaron la prevalencia y 1 reportó la progresión de la enfermedad y la mortalidad.…”

“…Se observó un incremento de la prevalencia conforme avanza el promedio de edad de los participantes (59.1% de prevalencia en pacientes entre 56 a 84 años de edad) y en estudios de medicina general (42.7% en pacientes de 59.6 años de edad promedio) en comparación a un estudio de población general en EE.UU. (12.5% de prevalencia en pacientes de 47 años de edad promedio) 21 . Hay poca información sobre la progresión de la enfermedad, de acuerdo a un estudio retrospectivo conducido en EE.UU.…”

Biomarkers in Heart Failure: From Research to Clinical Practice

“…However, the reduction in mortality among HF patients with different HF phenotypes is regarded to be occurring at a less rapid pace than expected, thus pointing to an era of endless HF epidemic [5]. A recent systematic review established that the estimated prevalence of preclinical stages of HF (stages A and B) reached up to 43% among high-risk patients with hypertension and in men [6]. The 7-year risk of incidence of symptomatic HF (stages C and D) and all-cause mortality reached up to 9.8% and 5.4%, respectively [6].…”

“…A recent systematic review established that the estimated prevalence of preclinical stages of HF (stages A and B) reached up to 43% among high-risk patients with hypertension and in men [6]. The 7-year risk of incidence of symptomatic HF (stages C and D) and all-cause mortality reached up to 9.8% and 5.4%, respectively [6]. Early diagnosis and intervention are considered to slow or even stop the progression of HF from the asymptomatic to symptomatic stages.…”